β-Caryophyllene ameliorates the development of experimental autoimmune encephalomyelitis in C57BL/6 mice

Area of Science:

• Immunology
• Neuroscience
• Pharmacology

Background:

• Multiple sclerosis (MS) is a prevalent autoimmune inflammatory and demyelinating disease of the central nervous system.
• Experimental autoimmune encephalomyelitis (EAE) serves as a key animal model for investigating MS pathogenesis.
• Beta-caryophyllene (BCP), a natural sesquiterpene, is recognized for its potent anti-inflammatory properties.

Purpose of the Study:

• To investigate the in vitro and in vivo immunomodulatory effects of BCP on EAE in C57BL/6 mice.
• To assess the therapeutic potential of BCP in mitigating the clinical and pathological manifestations of EAE.

Main Methods:

• BCP was evaluated in vitro on splenocytes from EAE-induced mice and administered orally in vivo to EAE mice.
• Clinical scores, body weight, cytokine production (IFN-γ, TNF-α, IL-17), and oxygen radicals (H₂O₂, NO) were measured.
• Immunological responses were assessed using ELISA, and central nervous system (CNS) sections were analyzed histopathologically.

Main Results:

• In vitro, BCP inhibited the production of H₂O₂, NO, IFN-γ, and TNF-α in cultured cells from EAE mice.
• In vivo, BCP treatment significantly reduced EAE clinical scores, severity, and the production of H₂O₂, NO, TNF-α, IFN-γ, and IL-17.
• Histopathological analysis revealed that BCP treatment markedly decreased inflammatory infiltrates and neurological damage in the CNS of EAE mice.

Conclusions:

• BCP demonstrates significant therapeutic action in EAE, with effects comparable to healthy animals at higher doses.
• BCP effectively modulates immune responses, reduces inflammatory markers, and attenuates CNS damage in an MS model.
• BCP holds promise as a potential therapeutic agent for multiple sclerosis and related inflammatory neurological conditions.